Literature DB >> 10995013

Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cells.

J Dürig1, C Rosenthal, A Elmaagacli, C Heyworth, K Halfmeyer, C Kasper, J Novotny, U Dührsen.   

Abstract

We compared the biological effects of the CXC chemokine SDF-1alpha on immunomagnetically purified CD34+ cells isolated from human normal bone marrow (NBM), leukapheresis products (LP) and patients with chronic myeloid leukaemia (CML). LP CD34+ cells showed a significantly stronger migration response to SDF-1alpha (100 ng/ml) than CD34+ cells isolated from the peripheral blood (PB) of CML patients (P < 0.05). The chemotactic response to SDF-1alpha was also reduced in CML BM CD34+ cells in comparison to NBM CD34+ cells but the observed differences were not statistically significant. In analogy to normal CD34+ cells circulating CML PB CD34+ cells were less responsive to SDF-1alpha than their BM counterparts (P < 0.05). Furthermore, SDF-1alpha elicited similar concentration-dependent growth suppressive effects on normal and CML CD34+ cells (P > 0.05) in colony-forming cell assays. We then demonstrated that SDF-1alpha triggers intracellular calcium increases in CD34+ cells and there were no differences in the time course and dose response characteristics of normal and CML CD34+ cells. The reduced migration response to SDF-1alpha in CML CD34+ cells was not due to a down-regulation of the SDF-1alpha receptor CXCR-4 as flow cytometric analysis revealed similar CXCR-4 expression levels on NBM, LP, CML PB and CML BM CD34+ cells (P > 0.05). Finally, no differences in the modulation of CXCR-4 levels in response to SDF-1alpha and serum were observed in CML and normal CD34+ cells. Our data suggest that the impaired chemotactic response of CML CD34+ cells to SDF-1alpha is not caused by a lack or complete uncoupling of CXCR-4, but may be due to an intracellular signalling defect downstream of the receptor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10995013     DOI: 10.1038/sj.leu.2401875

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

1.  Inhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cells.

Authors:  Weidong Yu; Xiaolin Sun; Hongxing Tang; Yunxia Tao; Zonghan Dai
Journal:  Leuk Lymphoma       Date:  2010-06

2.  Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

Authors:  Yazan Alsayed; Hai Ngo; Judith Runnels; Xavier Leleu; Ujjal K Singha; Costas M Pitsillides; Joel A Spencer; Teresa Kimlinger; Joanna M Ghobrial; Xiaoying Jia; Ganwei Lu; Michael Timm; Ashok Kumar; Daniel Côté; Israel Veilleux; Karen E Hedin; G David Roodman; Thomas E Witzig; Andrew L Kung; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 3.  Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications.

Authors:  Irina Sadovnik; Harald Herrmann; Gregor Eisenwort; Katharina Blatt; Gregor Hoermann; Niklas Mueller; Wolfgang R Sperr; Peter Valent
Journal:  Exp Hematol       Date:  2017-04-27       Impact factor: 3.084

4.  Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia.

Authors:  Michael Willmann; Irina Sadovnik; Gregor Eisenwort; Martin Entner; Tina Bernthaler; Gabriele Stefanzl; Emir Hadzijusufovic; Daniela Berger; Harald Herrmann; Gregor Hoermann; Peter Valent; Thomas Rülicke
Journal:  Exp Hematol       Date:  2017-10-12       Impact factor: 3.084

5.  Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.

Authors:  Silvia Catellani; Ivana Pierri; Marco Gobbi; Alessandro Poggi; Maria Raffaella Zocchi
Journal:  PLoS One       Date:  2011-04-18       Impact factor: 3.240

6.  Differential effects of CXCR4 antagonists on the survival and proliferation of myeloid leukemia cells in vitro.

Authors:  Ha-Yon Kim; Ji-Young Hwang; Yoon-Suk Oh; Seong-Woo Kim; Hyo-Jin Lee; Hwan-Jung Yun; Samyong Kim; Young-Jun Yang; Deog-Yeon Jo
Journal:  Korean J Hematol       Date:  2011-12-27

7.  Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment.

Authors:  Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

Review 8.  Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Authors:  Axel Schulenburg; Katharina Blatt; Sabine Cerny-Reiterer; Irina Sadovnik; Harald Herrmann; Brigitte Marian; Thomas W Grunt; Christoph C Zielinski; Peter Valent
Journal:  J Hematol Oncol       Date:  2015-02-25       Impact factor: 17.388

Review 9.  Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms.

Authors:  Gregor Hoermann; Georg Greiner; Peter Valent
Journal:  Mediators Inflamm       Date:  2015-10-12       Impact factor: 4.711

10.  Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.

Authors:  Martin Culen; Marek Borsky; Veronika Nemethova; Filip Razga; Jiri Smejkal; Tomas Jurcek; Dana Dvorakova; Daniela Zackova; Barbora Weinbergerova; Lukas Semerad; Irina Sadovnik; Gregor Eisenwort; Harald Herrmann; Peter Valent; Jiri Mayer; Zdenek Racil
Journal:  Oncotarget       Date:  2016-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.